VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
4723
Agency Tracking Number:
4723
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
107 Lakefront Drive, Hunt Valley, MD, 21030
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ALLAN H FENSELAU
PRINCIPAL INVESTIGATOR
(301) 667-6880
Business Contact:
() -
Research Institute:
n/a
Abstract
VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S). THE IDENTIFICATION OF ONE OF THESE FACTORS AS "ANGIOGENIC COPPER" RAISES THE POSSIBILITY THAT COPPER CHELATORS CAN FUNCTION AS ANTIANGIOGENIC AGENTS. THE SPECIFIC AIMS OF THIS PHASE I STUDY ARE: (1) TO TEST VARIOUS COPPER CHELATORS FOR POSSIBLE ANTIANGIOGENIC EFFECTS IN THE CHICKENCHORIOALLANTOIC MEMBRANE (CAM) ASSAY; (2) TO EMPLOY AS ANGIOGENIC STIMULATORS IN THIS SYSTEM (A) COPPER-HEPARIN, A POLYPEPTIDE ANGIOGEN DERIVED FROM NERVOUS TISSUES; (B) A LOWMOLECULAR WEIGHT ANGIOGEN DERIVED FROM THE WALKER 256 RAT TUMOR; AND (C) VIABLE TUMOR CELLS FROM THIS SAME SOURCE; (3) TO ESTABLISH, USING IN VITRO METHODS, WHETHER AGENTS ACTIVE IN THE CAM ASSAY ARE INHIBITING VASCULAR ENDOTHELIAL CELL (EC) MIGRATION AND/OR PROLIFERATION OR ARE TOXIC TO EC AND/OR TUMOR CELLS; AND (4) BASED ON THE OUTCOME OF THE STUDIES RELATED TO THE FIRST THREE OBJECTIVES, TO PREPARE HEPARIN-(OR HEPARIN FRAGMENT) LINKED CHELATORS AND EMPLOY THESE NOVEL SUBSTANCES IN ANALOGOUS STUDIES. RESULTS FROM THESE STUDIES SHOULD ALLOW INDENTIFICATION OF NEW ANTI- ANGIOGENIC AGENTS. THESE SUBSTANCES CAN THEN BE SCREENED MORE THOROUGHLY IN A PHASE II STUDY FOR THEIR ANTICANCER PROPERTIES AGAINST VARIOUS TUMORS IN EXPERIMENTAL ANIMALS. THUS, THE ULTIMATE OBJECTIVE OF THESE STUDIES IS TO DEFINE NOVEL ANTIANGIOGENIC AGENTS THAT WILL PROVIDE IMPROVED MEANSFOR CONTROLLING TUMOR GROWTH AND SPREAD.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government